切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2016, Vol. 05 ›› Issue (04) : 159 -162. doi: 10.3877/cma.j.issn.2095-3216.2016.04.004

所属专题: 文献

专家论坛

终末期糖尿病肾病患者透析方式的选择
关天俊1()   
  1. 1. 361004 厦门大学附属中山医院肾内科
  • 收稿日期:2016-04-21 出版日期:2016-08-28
  • 通信作者: 关天俊
  • 基金资助:
    2015年福建省自然科学基金(2015J01532)

Choice of dialysis modality for patients with end-stage diabetic nephropathy

Tianjun Guan1,()   

  1. 1. Department of Nephrology, Zhongshan Hospital Affiliated to Xiamen University School of Medicine, Xiamen 361004, China
  • Received:2016-04-21 Published:2016-08-28
  • Corresponding author: Tianjun Guan
  • About author:
    Corresponding author: Guan Tianjun, Email:
引用本文:

关天俊. 终末期糖尿病肾病患者透析方式的选择[J/OL]. 中华肾病研究电子杂志, 2016, 05(04): 159-162.

Tianjun Guan. Choice of dialysis modality for patients with end-stage diabetic nephropathy[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(04): 159-162.

糖尿病肾病(DN)是导致终末期肾脏病的重要病因之一。终末期DN患者可选择的透析方式包括血液透析和腹膜透析,而具体选择何种透析方式,需要综合考虑共存疾病、家庭情况、患者的独立性与积极性、耐受容量转移的能力、血管条件和/或腹部的状态、感染风险及感染史等。

Diabetic nephropathy (DN) is one of the major causes of end-stage renal disease (ESRD). Patients with end-stage DN can choose dialysis modality of either hemodialysis (HD) or peritoneal dialysis (PD), depending upon the following factors: comorbid disease, home conditions, independence and motivation of a patient, ability to tolerate volume shift, status of the vasculature and/or abdomen, risk and history of infection, and so on.

[1]
Xu Y,Wang L,He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-959.
[2]
Centers for Disease Control and Prevention (CDC). Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes- United States and Puerto Rico, 1996-2007[J]. MMWR Morb Mortal Wkly Rep, 2010, 59(42): 1361-1366.
[3]
Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006[J]. Am J Kidney Dis, 2006, 48(Suppl 1): S2-S90.
[4]
US Renal Data System. USRDS 2014 annual data report (2014): end-stage renal disease in the United States[CD/OL].

URL    
[5]
刘莉,王梅,李雪梅, 等. 北京市血液透析患者的透析时机的变迁[J]. 中国血液净化, 2014, 13(12): 855-859.
[6]
Cooper BA,Branley P,Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis[J]. N Engl J Med, 2010, 363(7): 609-619.
[7]
Lameire NH. The impact of residual renal function on the adequacy of peritoneal dialysis[J]. Contrib Nephrol, 1998, 124: 76-93.
[8]
van Olden RW,van Acker BA,Koomen GC, et al. Contribution of tubular anion and cation secretion to residual renal function in chronic dialysis patients[J]. Clin Nephrol, 1998, 49(3): 167-172.
[9]
Moist Lm,Vonesh EF,Gotcg F, et al. Predictors of loss of residual renal function among new dialysis patients[J]. J Am Soc Nephrol, 2000, 11(3): 556-564.
[10]
Jansen MA,Hart AA,Korevaar JC, et a1. Predictors of the rate of decline of residual renal function in incident dialysis patients[J]. Kidney Int, 2002, 62(3): 1046-1053.
[11]
Canada USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes[J]. J Am Soc Nephrol, 1996, 7(2): 198-207.
[12]
Glorieux G,Vanholder R. New uremic toxins-which solutes should be removed?[J]. Contrib Nephrol, 2011, 168: 117-128.
[13]
Saran R,Li Y,Robinson B, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States[J]. Am J Kidney Dis, 2015, 66(1 Suppl 1): S1-S305.
[14]
Hou F,Jiang J,Chen J, et a1. China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysis[J]. BMC Nephrol, 2012, 13: 94.
[15]
Morioka T,Emoto M,Tabata T, et a1. Glycemic control is a predictor of survival for diabetic patients on hemodialysis[J]. Diabetes Care, 2001, 24(5): 909-913.
[16]
Simic-Ogrizovic S,Backus G,Mayer A, et al. The influence of different glucose concentrations in haemodialysis solutions on metabolism and blood pressure stability in diabetic patients[J]. Int J Artif Organs, 2001, 24: 863-869.
[17]
Salamon K,Woods J,Paul E, et al. Peritoneal dialysis patients have higher prevalence of gastrointestinal symptoms than hemodialysis patients[J]. J Ren Nutr, 2013, 23(2): 114-118.
[18]
Wang T,Heimbürger O,Bergström J, et al. Nutritional problems in peritoneal dialysis: an overview[J]. Perit Dial Int, 1999, 19 Suppl 2: S297-S303.
[19]
Cianciaruso B,Brunori G,Kopple JD, et al. Cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and hemodialysis patients[J]. Am J Kidney Dis, 1995, 26(3): 475-486.
[20]
Bossola M,Muscaritoli M,Tazza L, et al. Malnutrition in hemodialysis patients: What therapy?[J]. Am J Kidney Dis, 2005, 46(3): 371-386.
[21]
Chung S,Koh ES,Shin SJ, et al. Malnutrition in patients with chronic kidney disease[J]. Open J Intern Med, 2012, 2: 89-99.
[22]
Pulliam J,Li NC,Maddux F, et al. First-year outcomes of incident peritoneal dialysis patients in the United States[J]. Am J Kidney Dis, 2014, 64(5): 761-769.
[23]
Collins AJ,Foley RN,Herzog C, et al. US Renal Data System 2012 Annual Data Report[J]. Am J Kidney Dis, 2013, 61(1 Suppl 1): e1-e476.
[24]
Miskulin DC,Meyer KB,Athienites NV, et al. Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study[J]. Am J Kidney Dis, 2002, 39(2): 324-336.
[25]
McDonald SP,Marshall MR,Johnson DW. Polkinghorne KR. Relationship between dialysis modality and mortality[J]. J Am Soc Nephrol, 2009, 20(1): 155-163.
[26]
Yeates K,Zhu N,Vonesh E, et al. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada[J]. Nephrol Dial Transplant, 2012, 27(9): 3568-3575.
[27]
US Renal Data System. USRDS 2009 annual data report (2009): Atlas of chronic kidney disease and end-stage renal disease in the United States[CD/OL].

URL    
[28]
Ekart R,Hojs R. Obese and diabetic patients with end-stage renal disease: Peritoneal dialysis or hemodialysis?[J]. Eur J Intern Med, 2016, 32: 1-6.
[1] 诸琴红, 夏典平, 葛芳娣, 崔大伟. 抗氧化和炎症指标在糖尿病肾病患者中的临床意义[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 307-311.
[2] 费扬, 赵晗希, 孙丽琴, 楼琴华, 胡骏程. 银杏叶提取物对糖尿病肾病患者的疗效及其对尿液外泌体miR-342-3p的干预研究[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(03): 219-224.
[3] 中华医学会器官移植学分会, 中国医疗保健国际交流促进会肾脏移植学分会. 中国胰肾联合移植临床诊疗指南[J/OL]. 中华移植杂志(电子版), 2024, 18(03): 129-147.
[4] 吴红兵, 王志维, 李罗成, 任宗力, 胡俊霞, 宋鹏, 阮永乐. 心肾联合移植治疗终末期心肾疾病二例经验总结[J/OL]. 中华移植杂志(电子版), 2022, 16(06): 369-372.
[5] 张今宜, 李月红. 慢性肾脏病患者接种新型冠状病毒疫苗有效力及接种策略的研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(02): 97-100.
[6] 程莉, 章晓良. 血尿酸和胱抑素C与糖尿病视网膜病变患者合并糖尿病肾病的关系及影响因素[J/OL]. 中华肾病研究电子杂志, 2023, 12(04): 194-199.
[7] 邱岭, 朱旭丽, 浦坚, 邢苗苗, 吴佳玲. 糖尿病肾病患者肠道菌群生态特点与胃肠道功能障碍的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 453-458.
[8] 白璐, 李青霞, 冯一卓, 刘雪倩, 刘若琪, 曲卓敏, 赵凌霞. 丁酸盐治疗糖尿病肾病的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(03): 303-308.
[9] 谭莹, 朱鹏飞, 李楠, 黄莉吉, 周希乔, 严倩华, 余江毅. 火把花根片联合黄葵胶囊治疗高或极高进展风险糖尿病肾病的临床探索[J/OL]. 中华临床医师杂志(电子版), 2024, 18(02): 171-177.
[10] 黄莉吉, 王婷, 朱鹏飞, 刘敬顺, 余江毅, 谢绍锋. 芪葵颗粒联合火把花根片对G3A3期糖尿病肾病的疗效及对血清miRNA-21的影响[J/OL]. 中华临床医师杂志(电子版), 2023, 17(12): 1247-1252.
[11] 邬秋俊, 向茜. 甘油三酯-葡萄糖指数与2型糖尿病微血管并发症相关性的研究进展[J/OL]. 中华临床医师杂志(电子版), 2023, 17(10): 1109-1112.
[12] 张赟辉, 罗军, 刘栗丽, 汪宏, 耿克明. 腹膜透析与血液透析对老年终末期肾病患者营养状况及炎症反应的影响[J/OL]. 中华临床医师杂志(电子版), 2023, 17(04): 419-423.
[13] 张梅, 陈卉, 李转霞, 王瑞, 李林娟. Metrnl和NLRP3炎症小体:糖尿病肾病的潜在诊断标志物[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(03): 193-199.
[14] 刘倩影, 刘雪彦, 周佩如, 胡申玲, 叶倩呈, 黄洁微. 糖尿病肾病患者血液透析期间低血糖管理的证据总结[J/OL]. 中华肥胖与代谢病电子杂志, 2023, 09(01): 22-27.
[15] 白明悦, 杨淑娜, 胡红梅, 胡文立. 透析患者脑小血管病患病情况的研究现状及其机制探讨[J/OL]. 中华脑血管病杂志(电子版), 2023, 17(05): 505-509.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?